Oncology
ESMO26: Taiho Oncology on improving the lives of patients wi...
Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.
Oncology
ESMO26: Lowering toxicity, extending lives, with Syncromune
As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.
Patients
Sponsored
Digital
AI governance & cybersecurity: Torridon Cyber’s Robbie Tyrie
Robbie Tyrie, founder and managing director of Torridon Cyber, talks cybersecurity when it comes to AI, pharma companies, and health systems.
Sales & Marketing
AI and pharma launch - Within3’s Jason Smith
Jason Smith, CTO of AI and analytics at Within3, discusses data-fuelled agile launches and smarter decision-making.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
